New Delhi – Drug firm Glenmark Pharmaceuticals has launched the antiviral drug Favipirvir under the brand name Fabiflu for the treatment of mild to moderate Covid-19 patients, after getting approval for manufacturing and marketing from the Drugs Controller General of India (DCGI).. Based on a price per 103 for a tablet. the prescription-based drug will be available as a 200 mg tablet at an MRP of at 3500 for a strip of 34 tablets.
10 Things to know about the New Covid-19 medicine.
1- The recomended dose of favivirvir is 1800 mg twice daily, followed by 800 mg twice daily. It is a prescription medicine.
2- The drug will be available through hospitals and retail channels, Glenmark said.
3- Dr, Romel Tikou, Associate Director, Internal Medicine, Max Healthcare, said the drug could be a “potential game-changer”. “We do not have much data, but whatever the data we have shows that it is promising. We will have a clear information about the efficacy of the drug in the next two months. The initial report is promising which means that they (Glenmark). It works he told PTI. It is to be deliverd at an early stage and is a potential game changer.Because it can be given in a tablet form and thus it is easy and relatively inexpensive.
4- Glenmark is producing active pharmaceutical ingredients (APIs) for medicine at its Ankleshwar plant, while manufacturing at its Baddi plant.
5- Favipiravir can be used for corona virus patients with mild to moderate Covid-19 symptoms with co-morbid condition such as diabetes and heart disease, Glenmark said.
6- It provides a rapid reduction in viral load within four days and provides rapid symptomatic and radiological improvment. the drug maker stated that favipiravir showed clinical improvement of up to 88 percent in mild to moderate Covid-19 cases.
7- Favipiravir is supported by strong clinical evidence, which shows encouraging results in patients with mild to moderate Covid-19. It provides broad spectrum RNA virus coverage with notable clinical improvment in the 20-90 plus age group.
8- Glenmark was the first company in india to recieve the approval of the drug regulator to conduct phase-3 clinical trials of Favipiravir anti-viral tablets for covid-19 patients.
9- Favipirvair is a subsidiary of FujiFilm Corporation, is a generic version of Japan’s Avigan of FujiFilm Toyama Chemical.
10- Considering a minimum of two strips per patient, Glenmark will be able to provide Fabiflu for about 82,500 patients in the first month itself.